TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06406387

Intervention type: DIAGNOSTIC_TEST
Intervention: ATRX/DAXX immunohistochemistry
Description: Immunohistochemistry will be performed using an Autostainer Leica (Leica Biosystems) according to the manufacturer's instructions. Four μm formalin-fixed paraffin-embedded sections will be immunostained with antibodies for Cytokeratin AE1/AE3 (AE1-AE3, 1:100 dilution, Novocastra/United Kingdom) Chromogranin A (DAK-A3, 1:2500, Dako/Denmark), and Synaptophysin (27G12, 1:100, Novocastra), Ki67 (MIB1, 1:100, Dako/Denmark), ATRX (1:400, Sigma-Aldrich), DAXX (1:200, Sigma-Aldrich). After antigen retrieval, immunostaining will be performed in an automated Bond instrument (Vision-Biosystem, Leica, Milan, Italy) using a sensitive peroxidase-based 'Bond polymer Refine' detection system.

Intervention type: DIAGNOSTIC_TEST
Intervention: ATRX/DAXX immunohistochemistry
Description: Immunohistochemistry will be performed using an Autostainer Leica (Leica Biosystems) according to the manufacturer's instructions. Four μm formalin-fixed paraffin-embedded sections will be immunostained with antibodies for Cytokeratin AE1/AE3 (AE1-AE3, 1:100 dilution, Novocastra/United Kingdom) Chromogranin A (DAK-A3, 1:2500, Dako/Denmark), and Synaptophysin (27G12, 1:100, Novocastra), Ki67 (MIB1, 1:100, Dako/Denmark), ATRX (1:400, Sigma-Aldrich), DAXX (1:200, Sigma-Aldrich). After antigen retrieval, immunostaining will be performed in an automated Bond instrument (Vision-Biosystem, Leica, Milan, Italy) using a sensitive peroxidase-based 'Bond polymer Refine' detection system.
Study: NCT03291470

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C
Description: 2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: 2 mL normal saline intraarticular injection
Study: NCT05702411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air Stacking Technique
Description: Air Stacking lung reexpansion technique after aspiration with expiratory pause in a closed system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Air Stacking Technique
Description: Aspiration technique in a closed system of aspiration with an expiratory pause of 10 seconds.
Study: NCT04481113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study: NCT05939817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cells (UC-MSC)
Description: Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)
Description: Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide (TA)
Description: Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
Study: NCT06278116

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aligners cleansing with water
Description: The product is masked in a spraying bottle without any labels. Once a day, for 14 days, the patient sprays the product on the aligner before cleaning it with a soft bristle toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aligners cleansing with dish soap Svelto
Description: the product is masked in a transparent bottle without any labels. Once a day, for 14 days, the patient puts the product on the aligner before cleaning it with a soft bristle toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aligners cleansing with Polident Antibacterial Denture Cleaner
Description: the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient dissolves the tablet in a glass full of warm water (30-35 °C), then the aligner is placed inside it for 5 minutes. Afterward the aligner is rinsed under fresh running water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aligners cleansing with Invisalign Cleaning Crystals
Description: the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient dissolves the crystals in a glass full of warm water (30-35 °C) mixing with a spoon for 20 seconds; then, the aligner is placed inside the glass for 15 minutes. Afterward, the aligner is rinsed under fresh running water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aligners cleansing with Geldis
Description: the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient puts the product on the aligner before cleaning it with a soft toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
Study: NCT05197686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen theraphy with high flow nasal cannule
Description: Oxygen theraphy with high flow nasal cannule

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen theraphy with mask with reservoir
Description: Oxygen theraphy with mask with reservoir
Study: NCT06240858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal hernia repair.
Description: The TAPP group used self-gripping mesh for laparoscopic transperitoneal preperitoneal hernia repair.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein hernia repair.
Description: The Lichtenstein group used self-gripping mesh for Lichtenstein hernia repair.
Study: NCT05537519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phage Therapy
Description: 3-phage cocktail comprised of HP3, HP3.1 and ES19
Study: NCT04857775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Child Health (ATTACH) Parenting Program
Description: ATTACH™ provides parent training to address Reflective Function (RF) of parents affected by a broad array of toxic stressors. RF, defined as the ability to have insight into one's own and one's child's mental states, feelings, thoughts and intentions, underpins parental sensitivity and responsiveness and is undermined by the experience of current or past stress. Parents require high RF to respond sensitively/appropriately to their children and thus promote secure parent-child attachments, essential for child MEB health. ATTACH™ consists of 10-12 \~45-minute clinic visits with dyadic (mother and infant) and triadic (mother, infant, and co-parent) elements, with a trained facilitator, who may be a nurse, social worker or other allied health professional.
Study: NCT06407583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ProMIO2.0 program
Description: ProMIO2.0 is a lifestyle intervention carried out by physiotherapy and dietetics. They guide and encourage the participants to achieve the following behavioral goals:~* moderate/intensive exercise (e.g. walking) for 150-300 minutes per week~* Muscle-strengthening exercises 2x a week~* Supplemented with balance and flexibility exercises~* 1.2 grams of protein per kilogram of body weight per day (\~25-30 grams of protein per meal, 4x/day) The combination of consultations, information sessions and on-site training at the physiotherapist should ensure that participants acquire the necessary knowledge, awareness and skills to adopt the health behavior in daily life. Materials such as posters, pedometers and videos are used for support.~The intervention is divided into 2 phases, which indicate the degree of professional guidance:~1. intensive guidance (month 0 - 3)~2. average guidance (months 4 - 6)
Study: NCT06247618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: visor
Description: The treatment will have a duration of 4 weeks, with the execution of two sessions per week with the use of a viewer positioned on the head that allows users to navigate and interact in real time with a three-dimensional (3D) environment
Study: NCT04481113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tosylate Monohydrate
Description: Given PO
Study: NCT06339216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)
Description: Adebrelimab injection：Intravenous infusion, fixed dose 1200 mg, Day 1, Q3W. Until disease progression or intolerable toxicity occurs, the infusion should be administered over 30 to 60 minutes and over a maximum of 2 hours. When adalimumab is administered in combination with chemotherapy, Adebrelimab should be administered as an intravenous infusion first, followed by chemotherapy at least 30 minutes apart.~Apatinib mesylate：Administered orally, 250 mg/time, once daily, orally, half an hour after meals (the time of daily administration should be as same as possible), with warm boiled water, the missed dose of Apatinib during the course of treatment cannot be supplemented.~Paclitaxel for Injection(Albumin Bound)：Intravenous infusion, 250 mg/m2, day 1, Q3W, intravenous drip over 30 minutes.
Study: NCT05056792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric strength training for 8 week
Description: Plyometric training for 8 week

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric strength training for 8 week
Description: Plyometric training for 8 week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional training
Description: Conventional training for 8 week

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional training
Description: Conventional training for 8 week
Study: NCT06287710

Intervention type: PROCEDURE
Intervention: Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).
Description: Study of diagnostic accuracy (non-interventional, prospective, monocentric). Fluid expansion will be delayed for a few minutes while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard test). This will allow to test the diagnostic performance of the index test for the prediction of fluid responsiveness.~The index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline (stroke volume, cardiac output, left ventricular ejection fraction), During a standardized abdominal compression (stroke volume),After the 10 to 20ml/kg fluid expansion prescribed by the physician in charge (cardiac output).
Study: NCT04340258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cesium-131
Description: Cs-131 brachytherapy seed is a low-energy-gamma isotope that is contained in a titanium capsule. Dosing will be determined by a radiation oncologist study team member based on CT scan and intraoperative findings. The number of seeds and spacing will be outlined preoperatively based on the proposed square area of exposure in the resection bed. The plan is to deliver a total of 60-70Gy of radiation to the site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks. The drug will be infused through a peripheral line or an indwelling catheter. The first dose will be given 2 weeks prior to surgery. Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months. Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
Study: NCT05510219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rapid infusion of obinutuzumab
Description: This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital. All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
Study: NCT05519059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Pelareorep at 1.5×10\^10 TCID50, 3×10\^10 TCID50, 4.5×10\^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m\^2 on Day 1/8/15 per cycle
Study: NCT06496022

Intervention type: DIAGNOSTIC_TEST
Intervention: Frail scale
Description: FRAIL scale for determining frailty (tired most of the time in the last 4 weeks; the presence of more than 5 diseases; difficulty or inability when climbing stairs and walking around the block; weight loss of more than 5% of the previous weight in the last 6 months).

Intervention type: DIAGNOSTIC_TEST
Intervention: Barthel scale
Description: The Barthel scale is used to determine the degree of independence in daily life, the patient's household activity, the assessment of the quality of life and the necessary care.

Intervention type: DIAGNOSTIC_TEST
Intervention: SARC-F
Description: The SARC-F scale is used to identify muscle dysfunction (difficulty lifting things over 4.5 kg, walking around the room, difficulty climbing from a chair and up 10 steps, whether the respondent has fallen in the last year).

Intervention type: DIAGNOSTIC_TEST
Intervention: FRAX
Description: FRAX Scale (Kazakhstan platform) fracture and osteoporosis risk assessment on the website https://frax.shef.ac.uk/FRAX/tool.aspx?country=72

Intervention type: DIAGNOSTIC_TEST
Intervention: Mini-Cog scale
Description: The Mini-Cog scale defines cognitive impairment (cognitive impairment - when scoring less than 3 points based on remembering three words and evaluating the task of drawing a clock).

Intervention type: DIAGNOSTIC_TEST
Intervention: dynamometry
Description: carpal dynamometry (sarcopenia is exhibited at values below 26 units for men and below 16 units for women).
Study: NCT05755425

Intervention type: DEVICE
Intervention: CPAP
Description: CPAP will be delivered with a CPAP valve with venturi flow system with full-face mask. Treatment will start with CPAP set at 10cmH2O and FiO2 60% to target a SpO2 ≥90% or PO2 ≥60mmHg and then adjusted according to SpO2, respiratory distress and clinical tolerance

Intervention type: DEVICE
Intervention: HFNO
Description: HFNO will be applied initially at maximal settings: 100% FiO2, flow rate 60 L/min and temperature 37C . Within 1 to 2 h, the HFNO settings should be titrated based on patients respiratory rate (\<25-30 per minute), SpO2 (92-96%) and comfort
Study: NCT05252481

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Eight sessions of transcranial current direct stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Eight sessions of transcranial current direct stimulation (sham)
Study: NCT06016465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Two 4mg pills

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo pills
Study: NCT05346549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High energy preload
Description: Tests the extent to which participants reduce their food intake at a meal following ingestion of a high energy preload drink.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy preload
Description: Tests the amount participants eat at a meal following ingestion of a low energy preload drink
Study: NCT05813587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meplazumab for injection
Description: Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study: NCT06041464

Intervention type: OTHER
Intervention: cell culture
Description: isolation of cell culture

Intervention type: OTHER
Intervention: cell culture
Description: isolation of cell culture
Study: NCT05285020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alter G
Description: It is anti-gravity treadmill treatment on Alter G. They will start with a 30-50% body weight load during the first week that will be progressively increased to 50-70% during the second (5% more each day during the 10 sessions as far as possible).~The slope will be 0% and the speed 2-3km/h the first week and 3-4 km/h the second. Treatment will be performed during 15 minutes for two weeks (10 sessions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parallel bars and Scale
Description: It is a re-education of the gait at the parallel bars with a progressive load in scale controlled by the patient during 10 minutes for two weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Parallel bars and Scale
Description: It is a re-education of the gait at the parallel bars with a progressive load in scale controlled by the patient during 10 minutes for two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation protocol
Description: It is the hospital's standard protocol for that injuries once a day for two weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard rehabilitation protocol
Description: It is the hospital's standard protocol for that injuries once a day for two weeks.
Study: NCT06451549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syndi recommender system for mental health apps
Description: Syndi is a mental health app recommendation system. It provides personalised suggestions of apps to help users self-manage their mental health based on a clinical assessment.
Study: NCT04775498

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face psychoeducation group
Description: All of the investigation centers participating in this study have a psychoeducation programme on bipolar disorders labeled and monitored by their Regional Health Agency. For this, he must respect the decree of January 14, 2015 relating to the specifications of therapeutic education programs for the patient. Patients will be receive by an investigator, for inclusion and baseline evaluation and at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIMPLe mobile application
Description: The experimental intervention consists of 12 months use SIMPLe smartphone application who has been developed by the Barcelona Institute of neuroscience. The purpose of this application is to deliver individualized psychoeducation messages to the patient's clinical condition. The psychoeducational messages correspond to the contents of the different modules and sessions carried out in face-to-face psychoeducation groups (Colomm \& Vieta ; 2015). Patients will be receive by an investigator for inclusion and baseline evaluation, at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
Study: NCT05450640

Intervention type: OTHER
Intervention: satisfaction survey
Description: 1 eQuestionnaire per patient completed during study
Study: NCT05027048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium chloride
Description: See arm description above

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: see arm description above
Study: NCT05506514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water immersion
Description: Comparison of 3 different water temperatures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water immersion
Description: Comparison of 3 different water temperatures

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water immersion
Description: Comparison of 3 different water temperatures
Study: NCT04960852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a single shade structurally colored universal resin composite
Description: Omnichroma is a single shade composite that is claimed to have blending effect with the tooth color, thus eliminate shade matching procedures during restorative treatment
Study: NCT06424587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: : In addition to the routine practice of the clinic, the pediatric patients in this group listened to music through headphones for 20 minutes just before the procedure to reduce the child's anxiety and fear. The therapeutic effect of music was used. Before the study, children between the ages of 6 and 12 who were inpatients at the clinic were asked what music they most liked to listen to, what kind of music they liked, and what their favorite artists and songs were. The music was selected based on the children's answers. In addition, the researcher added children's songs by a musician named Banu Kanıbelli
Study: NCT06230029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Music will be played through individual headphones (BOSE AE2®). The headphones give the impression of personalized music that only the patient can hear. Patients will have a mask over their eyes to limit visual aggression. The songs will be pre-recorded on a digital tablet (Samsung Galaxy®) allowing the broadcasting of music programs. Patients will have the choice to listen to a song according to their musical preferences among 16 different musical styles. The volume will be adapted to the level that suits the patient.